Abstract
Glioblastoma is a devastating brain cancer that currently has no cure. Most cancer treatments, such as radiation therapy and chemotherapy drugs temozolomide and gemcitabine kill cancer cells by inflicting damage to the DNA. However, glioblastoma cells have pathways to repair DNA damage, therefore are resistant to cancer treatments. This thesis explores another drug called LY2606368, a CHK1 inhibitor, as a method to sensitise glioblastoma cells to radiation therapy, temozolomide and gemcitabine. Combining radiation therapy, temozolomide or gemcitabine with LY2606368 increased the amount of DNA damage which associated to greater glioblastoma cell death and improved survival of mice models of glioblastoma.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Thesis sponsors | |
| Award date | 18 Oct 2021 |
| DOIs | |
| Publication status | Unpublished - 2021 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - HOANG, Tracy Seymour - 2021
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.